Answers are grounded in this paper and cite their sources.
Nanotechnology-based drug delivery systems (NDDS) use engineered materials and structures at the nanoscale to alter how therapeutic agents are formulated, transported, released and cleared. Their development addresses several limitations of conventional dosage forms, including poor aqueous solubility, chemical instability, rapid degradation, limited tissue penetration, nonspecific distribution and dose-limiting toxicity. Liposomes, lipid nanoparticles, polymeric nanoparticles, polymeric micelles, dendrimers, albumin-based carriers, inorganic nanoparticles and hybrid systems represent major platform families. Each has distinct composition, drugloading mechanisms, release behaviour, manufacturing requirements and biological interactions. The field has progressed from proof-of-concept formulations to clinically established products. Liposomal doxorubicin, albumin-bound paclitaxel and lipid nanoparticle delivery of small interfering RNA demonstrate that nanoscale formulation can produce clinically useful changes in drug disposition or enable delivery of otherwise difficult therapeutic cargo. Lipid nanoparticles have also become an important platform for mRNA vaccines and other nucleic-acid medicines. These successes should not be interpreted as evidence that every nanoparticle improves efficacy or targeting: clinical benefit depends on the drug, carrier, disease, route, patient population and quality of the supporting evidence (Allen and Cullis, 2013; Mitchell et al., 2021). This review examines the principles of NDDS design, major carrier classes, preparation and characterization, targeting and release mechanisms, therapeutic applications, clinical translation, safety, regulation and future perspectives. Particular attention is given to biological barriers, protein-corona formation, immune interactions, scale-up, stability and reproducibility. Nanocarriers can protect cargo and modify pharmacokinetics, but their performance in vivo is shaped by complex interactions with blood components, tissue architecture, cellular uptake pathways and clearance organs. A formulation that performs well in a simplified laboratory model may not reproduce the same behaviour in humans (Wilhelm et al., 2016; Hou et al., 2021). Emerging directions include stimuli-responsive delivery, biomimetic carriers, targeted RNA therapeutics, nanotheranostics, organ-on-chip testing, computational formulation design and more predictive preclinical models. Translation requires early consideration of critical quality attributes, manufacturing controls, regulatory expectations and patient-relevant outcomes. The overall conclusion is that nanotechnology is a versatile pharmaceutical platform rather than a universal solution. Its value must be demonstrated product by product through rigorous physicochemical characterization, biological testing, clinical evaluation and lifecycle quality management.
No takes yet. Share an insight, caveat, or question.
Soneja et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: